Perfil de la empresa · Healthcare

Becton Dickinson and Company

BDX · EE. UU.
Bolsa
EE. UU.
País / Región
USA
Fecha de salida a bolsa
1 de enero de 1987
Empleados
60.000
Sitio web
www.bd.com
Precio actual
$143.98
En vivo · 18 de junio de 2026
Puntuación de crecimiento Baillie
40/100
Floja
Valor intrínseco · Rango en tres niveles Precio actual $143.98 En vivo · Entre el rango conservador y el razonable

Rango de valoración compuesto · conservador $108–$125 / razonable $154–$178 / optimista $217–$249. A $143.98, Entre el rango conservador y el razonable.

Al publicar $147.63 (24 de mayo de 2026)

Aún no hay análisis sobre este valor en tu idioma.

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care

Capitalización39,02 mil MUS$
Ingresos (TTM)22,23 mil MUS$
EBITDA6157 MUS$
Margen neto5,12 %
ROE6,67 %
PER (TTM)24,71
PER previsto10,49
PEG1,11
BPA5,73 US$
Rentabilidad por dividendo2,88 %
Rango de 52 semanas125,21 US$ – 184,86 US$
Precio objetivo de analistas180,69 US$
Recomendación de analistas3.8 / 5

Datos de EODHD, mostrados en la moneda de reporte; solo a título informativo, no constituye asesoramiento de inversión.

Historia

PróximamenteEsta sección se está completando; vuelve pronto.

Posición en el sector

PróximamenteEsta sección se está completando; vuelve pronto.